The Centre for Drug Development news archiveThe Centre for Drug Development news archive
2023
- Cancer Research UK appoints new director to lead its Centre for Drug Development
- A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)
- Cancer Research UK and Guardant Health launch collaboration to advance cancer research and clinical development activities
- Cancer Research UK and the KWF Dutch Cancer Society enter partnership to bring multiple drugs into clinical development
- Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023
- Patients with rare cancers given hope by UK-led ‘drug-match’ trial
- Sosei Heptares and Cancer Research UK announce the dosing of the first patient in a Phase 1/2a trial with cancer immunotherapy drug HTL0039732
- New class of antibody drug shows promise for cancer patients
- Topline Phase 1 study results with VAC2 for the treatment of advanced non-small cell lung cancer
- Cancer Research UK joins European precision cancer medicine trial consortium
- Study Details | Phase I Study of MOv18 IgE
- Cancer Research UK signs multi-project collaboration with UCB to advance oncology antibody candidates
- Hummingbird Bioscience exercises its option to license clinical trial results from Cancer Research UK
2022
- Novartis joins Cancer Research UK trial for rare cancers
- App for patients on a clinical trial piloted by Cancer Research UK
- Precision medicine trial opens for rare adult and paediatric cancers
- Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
- Cancer Research UK reveals innovation engine underpinned by £400m portfolio of cutting-edge discovery science
- Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
- Study Details | A Phase I Trial of AZD3965 in Patients With Advanced Cancer
- Cancer Research UK and Teon Therapeutics announce first patient dosed in clinical trial for hard-to-treat solid cancers
- World Cancer Day: Celebrating Life-Saving Research
- Tailored Patient Involvement in Clinical Trials
- Cancer Research UK dose first patient in phase I/IIa trial of lung cancer immunotherapy vaccine
2021
- Cancer researchers across the UK join forces to find drugs for rare cancers
- Cancer Research UK announces first patient dosed in trial for hard-to-treat cancers
- Aleta Biotherapeutics and Cancer Research UK collaborate to advance blood cancer therapy into the clinic
- Funding bodies should foster partnerships between industry and academia
2020
- Teon Therapeutics Announces Approval for Collaboration with Cancer Research UK
- Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma
- Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program
- Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718